STRO - Sutro Biopharma, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
8.51
+0.01 (+0.12%)
As of 9:45AM EDT. Market open.
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close8.50
Open8.46
Bid8.35 x 1200
Ask8.64 x 1100
Day's Range8.45 - 8.51
52 Week Range6.00 - 12.75
Volume823
Avg. Volume154,492
Market Cap305.324M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
All
News
Press Releases
  • Sutro Biopharma Presents New Preclinical Data at 2020 AACR Virtual Annual Meeting II Suggesting Synergy between its STRO-002 Antibody-Drug Conjugate and Immune Checkpoint Inhibitors Resulting in Tumor Regression and Adaptive Anti-Tumor Immunity
    PR Newswire

    Sutro Biopharma Presents New Preclinical Data at 2020 AACR Virtual Annual Meeting II Suggesting Synergy between its STRO-002 Antibody-Drug Conjugate and Immune Checkpoint Inhibitors Resulting in Tumor Regression and Adaptive Anti-Tumor Immunity

    Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced the presentation of new preclinical data for its folate receptor alpha (FolRα) targeting antibody-drug conjugate, STRO-002, at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II from June 22-24, 2020. The data, being presented by Sutro's Chief Scientific Officer, Trevor Hallam, Ph.D., demonstrates STRO-002's immune-modulating properties and potentiation by PD-L1 blockade.

  • Scott+Scott Attorneys at Law LLP Announces Investigation into Sutro Biopharma, Inc. (STRO)
    Business Wire

    Scott+Scott Attorneys at Law LLP Announces Investigation into Sutro Biopharma, Inc. (STRO)

    Scott+Scott Attorneys at Law LLP announces investigation into Sutro Biopharma, Inc. (STRO) and encourages shareholders with losses to contact the Firm

  • Sutro Biopharma to Present New Preclinical Data on its STRO-002 Antibody-Drug Conjugate at the Upcoming AACR 2020 Virtual Meeting on June 22, 2020
    PR Newswire

    Sutro Biopharma to Present New Preclinical Data on its STRO-002 Antibody-Drug Conjugate at the Upcoming AACR 2020 Virtual Meeting on June 22, 2020

    Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced that the company will present new preclinical data for its folate receptor alpha targeting antibody-drug conjugate, STRO-002, at the American Association for Cancer Research (AACR) Virtual Annual Meeting II being held June 22-24, 2020.

  • GlobeNewswire

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sutro Biopharma, Inc. - STRO

    Pomerantz LLP is investigating claims on behalf of investors of Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Sutro and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

  • Sutro Biopharma Expands Senior Management with the Additions of Vice President of Clinical Development and Vice President of Finance and Controller
    PR Newswire

    Sutro Biopharma Expands Senior Management with the Additions of Vice President of Clinical Development and Vice President of Finance and Controller

    Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced the appointment of Craig Berman, M.D., as Vice President of Clinical Development and the promotion of Regina Cheng to Vice President of Finance and Controller.

  • Sutro Biopharma Adds Two Exceptional Leaders to Advisory Boards-- Carlos Paya, MD, PhD, and Lainie Martin, MD
    PR Newswire

    Sutro Biopharma Adds Two Exceptional Leaders to Advisory Boards-- Carlos Paya, MD, PhD, and Lainie Martin, MD

    Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced the appointments of Carlos Paya, M.D., Ph.D., as Chair of the Scientific Advisory Board and Lainie Martin, M.D., as a member of the Clinical Advisory Board.

  • Sutro Biopharma Announces Closing of $98.0 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares
    PR Newswire

    Sutro Biopharma Announces Closing of $98.0 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

    Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical stage drug discovery, development and manufacturing company focused on deploying its proprietary integrated cell-free protein synthesis platform, XpressCF®, to create a broad variety of optimally designed, next-generation protein therapeutics initially for cancer and autoimmune disorders, today announced the closing of its public offering of 12,650,000 shares of its common stock at a public offering price of $7.75 per share, which includes the exercise in full of the underwriters' option to purchase 1,650,000 shares of common stock. The gross proceeds from this offering were approximately $98.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Sutro.

  • ACCESSWIRE

    STRO Investor Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Sutro Biopharma, Inc. and Encourages Investors to Contact the Firm

    NEW YORK, NY / ACCESSWIRE / May 12, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sutro Biopharma, Inc. ("Sutro" or "the Company") ...

  • Sutro Biopharma Announces Pricing of $85.3 Million Public Offering
    PR Newswire

    Sutro Biopharma Announces Pricing of $85.3 Million Public Offering

    Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical stage drug discovery, development and manufacturing company focused on deploying its proprietary integrated cell-free protein synthesis platform, XpressCF®, to create a broad variety of optimally designed, next-generation protein therapeutics initially for cancer and autoimmune disorders, today announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a price to the public of $7.75 per share. The gross proceeds from this offering are expected to be approximately $85.3 million, before deducting underwriting discounts and commissions and other offering expenses payable by Sutro. Sutro has also granted the underwriters a 30-day option to purchase up to an additional 1,650,000 shares of common stock in connection with the public offering. All of the shares of common stock are being offered by Sutro. The offering is expected to close on or about May 14, 2020, subject to the satisfaction of customary closing conditions.

  • Sutro Biopharma Reports First Quarter 2020 Financial Results and Recent Business Highlights and Developments
    PR Newswire

    Sutro Biopharma Reports First Quarter 2020 Financial Results and Recent Business Highlights and Developments

    Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today reported its financial results for the quarter ended March 31, 2020 and its recent business highlights and developments.

  • Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer
    PR Newswire

    Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer

    Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced updated interim data regarding safety and anti-tumor activity results in heavily pre-treated patients with ovarian cancer from its on-going Phase 1 clinical trial (dose escalation phase) evaluating its folate receptor alpha (FolRα) antibody drug-conjugate (ADC) STRO-002. Sutro will host a conference call and live audio webcast on Monday, April 27, at 8 a.m. EDT to discuss the STRO-002 data.

  • Sutro Biopharma to Host Conference Call on April 27, 2020, to Provide Clinical Update on its STRO-002 Antibody-Drug Conjugate
    PR Newswire

    Sutro Biopharma to Host Conference Call on April 27, 2020, to Provide Clinical Update on its STRO-002 Antibody-Drug Conjugate

    Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, will host a conference call and live audio webcast on Monday, April 27, at 8 a.m. EDT to discuss updated dose escalation safety and efficacy data from the company's ongoing Phase I study of STRO-002 in ovarian and endometrial cancer that is being presented as a virtual poster at the AACR Virtual Annual Meeting. The virtual poster will be accompanied by a video presentation from Dr. Wendel Naumann of The Levine Cancer Institute.

  • Sutro Biopharma to Present Updated Clinical Data for its STRO-002 Antibody-Drug Conjugate at the AACR Virtual Annual Meeting on April 27, 2020
    PR Newswire

    Sutro Biopharma to Present Updated Clinical Data for its STRO-002 Antibody-Drug Conjugate at the AACR Virtual Annual Meeting on April 27, 2020

    Sutro Biopharma, Inc. (NASDAQ: STRO), today announced that the company has been invited to present updated clinical data from its STRO-002 antibody-drug conjugate (ADC) at the upcoming AACR Virtual Annual Meeting 2020. The submitted abstract and a virtual poster presentation, which will consist of further updated data accompanied by a video presentation from Dr. Wendel Naumann of The Levine Cancer Institute, will be available on demand on the AACR website (aacr.org) on Monday, April 27. Additionally, Sutro will host a conference call and live audio webcast on Monday, April 27 to discuss the STRO-002 clinical data, details of the call will be provided within the next week.

  • SutroVax Announces $110M Series D Financing to Advance Broadest-Spectrum Pneumococcal Vaccine Candidates to Prevent Pneumonia
    PR Newswire

    SutroVax Announces $110M Series D Financing to Advance Broadest-Spectrum Pneumococcal Vaccine Candidates to Prevent Pneumonia

    SutroVax, a biopharmaceutical company dedicated to the delivery of superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced the closing of a $110 million Series D preferred stock financing, co-led by new investors RA Capital Management and Janus Henderson Investors. All of SutroVax's existing institutional investors, including TPG Growth, Abingworth, Longitude Capital, Frazier Health Care Partners, Pivotal bioVenture Partners, Medixci, CTI Life Sciences, Roche Venture Fund, and Foresite Capital also participated in the financing.

  • Sutro Biopharma Reports Full Year 2019 Financial Results and Recent Business Highlights and Developments
    PR Newswire

    Sutro Biopharma Reports Full Year 2019 Financial Results and Recent Business Highlights and Developments

    Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today reported its financial results for the year ended December 31, 2019 and provided a preview of its planned activities for 2020.

  • Sutro Biopharma Announces Extension of First Cytokine Derivative Research Program Under Collaboration with Merck
    PR Newswire

    Sutro Biopharma Announces Extension of First Cytokine Derivative Research Program Under Collaboration with Merck

    Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced that Merck, known as MSD outside the U.S. and Canada, has extended the research term of the collaboration's first cytokine-derivative program by one year, which includes a payment to Sutro of an undisclosed amount. Sutro's collaboration with Merck was announced in July 2018 to develop therapeutics for cancer and autoimmune disorders.

  • Sutro Biopharma to Present Innovative Cancer Therapy Approach Using Precise Tumor Targeted Immunostimulants at World ADC London
    PR Newswire

    Sutro Biopharma to Present Innovative Cancer Therapy Approach Using Precise Tumor Targeted Immunostimulants at World ADC London

    Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced proof of concept data for a next generation dual conjugated combination immunostimulatory antibody drug conjugate (IADC). This breakthrough concept of a tumor targeting monotherapy, which simultaneously attacks tumor cells while stimulating a patient's own immune system, has the promise of generating long-term immunity.

  • Sutro Biopharma Expands Senior Management Team with the Appointments of Vice President of Immunobiology and Vice President of Business Development
    PR Newswire

    Sutro Biopharma Expands Senior Management Team with the Appointments of Vice President of Immunobiology and Vice President of Business Development

    Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced the expansion of its senior management team with the appointments of Kristin Bedard, Ph.D., as Vice President of Immunobiology, and Brunilda Shtylla as Vice President of Business Development.

  • Sutro Biopharma to Present at 38th Annual J.P. Morgan Healthcare Conference
    PR Newswire

    Sutro Biopharma to Present at 38th Annual J.P. Morgan Healthcare Conference

    Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced that the company will present at the 38th Annual J.P. Morgan Healthcare Conference on Thursday, Jan. 16, 2020, at 9:00 AM PST at the Westin St. Francis in San Francisco.

  • Sutro Biopharma Appoints James Panek to Board of Directors
    PR Newswire

    Sutro Biopharma Appoints James Panek to Board of Directors

    Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced the appointment of James P. Panek to its Board of Directors. Mr. Panek brings more than 40 years of experience in the biotech and pharmaceutical industry.

  • PR Newswire

    Sutro Biopharma to Present at the Stifel 2019 Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Nov. 19, 2019 /PRNewswire/ -- Sutro Biopharma, Inc. (STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced that Bill Newell, CEO of Sutro Biopharma, will present a corporate overview and business update at the Stifel 2019 Healthcare Conference on Wednesday, Nov. 20, 2019, at 9:10 a.m. EST at the Lotte New York Palace hotel in New York City. Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company.

  • PR Newswire

    Sutro Biopharma Reports Third Quarter 2019 Financial Results and Recent Business Highlights and Developments

    STRO-002 Initial Safety Data from an Ongoing Phase 1 Trial in Ovarian and Endometrial Cancers presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 29, 2019 STRO-001 ...

  • PR Newswire

    Sutro Biopharma Presents Encouraging Preliminary Clinical Data in Ongoing Phase I Study for STRO-002 Antibody-Drug Conjugate in Patients with Advanced Ovarian Cancer

    - Data is being presented as a poster today at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston - STRO-002 was well tolerated in patients with advanced relapsed and refractory ...

  • PR Newswire

    Sutro Biopharma Announces Presentation of STRO-002 for the Potential Treatment of Ovarian and Endometrial Cancer at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

    SOUTH SAN FRANCISCO, Calif. , Oct. 16, 2019 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that the company will present at the upcoming AACR-NCI-EORTC International Conference on ...

  • PR Newswire

    Sutro Biopharma to Receive Milestone Payment for Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors

    SOUTH SAN FRANCISCO, Calif., Oct. 8, 2019 /PRNewswire/ -- Sutro Biopharma, Inc. (STRO) today announced that it has achieved a milestone under its collaboration and license agreement with the healthcare division of Merck KGaA, Darmstadt, Germany and is entitled to receive a milestone payment.  The milestone was achieved upon the designation by Merck KGaA, Darmstadt, Germany of an undisclosed bispecific antibody drug conjugate (ADC) as a clinical development candidate with approval to advance to IND-enabling studies. This candidate was discovered using Sutro's XpressCF+™ drug discovery and manufacturing technology and includes a proprietary linker-warhead also discovered by Sutro.